Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Norgine
ClinicalTrials.gov Identifier:
NCT01493089
First received: December 13, 2011
Last updated: August 12, 2013
Last verified: August 2013
  Purpose

Heartburn is the main symptom of Gastroesophageal Reflux Disease (GERD), which, accompanied by acid regurgitation and other symptoms, has a substantial negative impact on a patients' quality of life. Although a number of treatment options are available, a more effective therapy is still required. The failure of proton pump inhibitors (PPIs) to completely resolve symptoms is an accepted problem, with approximately 25% of patients with GERD continuing to experience the symptoms of heartburn in spite of treatment. This study aims to demonstrate an earlier onset to relief of symptoms in patients suffering from heartburn associated with GERD using an immediate-release omeprazole/sodium bicarbonate formulation when compared with delayed-release omeprazole (Losec®).


Condition Intervention Phase
Gastroesophageal Reflux
Drug: Zegerid
Drug: Losec
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Multi-centre, Double-blind, Double-dummy, Randomised, Study to Assess the Superiority of Zegerid® 20 mg vs. Losec® 20 mg in the Rapid Relief of Heartburn Associated With GERD as on Demand Therapy

Resource links provided by NLM:


Further study details as provided by Norgine:

Primary Outcome Measures:
  • Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient [ Time Frame: up to 14 days following treatment ] [ Designated as safety issue: No ]
    Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more


Secondary Outcome Measures:
  • Median Time to Sustained Partial Response [ Time Frame: up to 14 days ] [ Designated as safety issue: No ]
    Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more

  • Median Time to Sustained Total Relief [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Time to sustained total relief, defined as zero severity (no heartburn) on a 9-point Likert severity scale, which is sustained for 45 minutes or more

  • Percentage of Patients Responding in 45 Minutes [ Time Frame: up to 14 days ] [ Designated as safety issue: No ]
    percentage of patients who have achieved sustained partial response, sustained response, or sustained total relief, by 45 minutes

  • Percentage of Patients Responding in 60 Minutes [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 60 minutes

  • Percentage of Patients Responding in 90 Minutes [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 90 minutes


Enrollment: 239
Study Start Date: April 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Zegerid
Treatment of heartburn with Zegerid
Drug: Zegerid
20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
Active Comparator: Losec
Treatment of heartburn with Losec
Drug: Losec
20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Study patients will be included in the study if they satisfy the following criteria:

  1. Male or female, between 18 and 75 years old.
  2. History of frequent episodes of heartburn associated with GERD for at least 2 3 days per week during 2-4 weeks before screening and have responded to standard PPI therapy in the past 12 months.
  3. Have not taken on-demand PPI therapy for > 3 consecutive days within 4 weeks before the screening period.
  4. The patient's written informed consent must be obtained prior to inclusion.
  5. Willing and able to complete the entire procedure and to comply with study instructions.
  6. Females of childbearing potential must employ an adequate method of birth control.

Inclusion criteria applicable to Screening period:

  1. Recorded at least 1 evaluable episode of heartburn on 2 separate days at level 4 or higher on the 9-point Likert severity scale (point 3 on a 0-8 point scale) prior to randomisation.
  2. Competent in the use and completion of the e-diary.

Exclusion Criteria:

Study patients will be excluded if they meet any of the following criteria:

  1. Age < 18 or > 75 years old.
  2. Intake of any medication for the purpose of the eradication of Helicobacter pylori (H. pylori) during the last 28 days before the start of the study.
  3. Intake of systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (≥ 3 consecutive days per week) during the last 28 days before the start of the study; except regular intake of enteric coated aspirin dosages up to 150 mg/d.
  4. Previously underwent acid-lowering surgery or other surgery of the oesophagus and/or upper gastrointestinal tract (excluding: appendectomy, cholecystectomy and polypectomy).
  5. History of co-existing disease that affects the oesophagus (e.g. Barrett's oesophagus, Zollinger-Ellison syndrome, oesophageal stricture), and have undergone an endoscopy with results of incomplete healing of erosions following standard PPI therapy within the last 3 months.
  6. History of active gastric or duodenal ulcers within 3 months of the first dose of the study drug or had acute upper gastrointestinal (GI) bleeding within last 6 months.
  7. Documented presence of severe renal or hepatic insufficiency.
  8. Known hypersensitivity to omeprazole.
  9. Concurrent participation in a study with an investigational drug or participation within 30 days of study entry.
  10. Females who are pregnant, or planning a pregnancy. Females of child bearing potential not using reliable methods of birth control.
  11. Clinically significant laboratory abnormality or disease which, in the opinion of the Investigator, will create a risk for the patient, obscure the effects of study treatment or interfere with study results.
  12. Received or require any of the following drugs within 2 weeks before the first dose of study or continue to need these drugs for concurrent therapy: theophylline, bismuth salts, warfarin, phenytoin, tacrolimus, diazepam, cyclosporine, disulfiram, benzodiazepines, barbiturates, antineoplastic agents, erythromycin, clarithromycin, sucralfate, clopidogrel or protease inhibitors.
  13. Taking concomitant medications that rely on the presence of gastric acid for optimal bioavailability (e.g. ketoconazole, ampicillin esters or iron salts).
  14. Onset of psychoactive medication (e.g. depressants, stimulants or hallucinogens) in the previous 6 months and during the entire course of the study.

Exclusion criteria applicable to Screening period:

  1. Recorded < 1 episode of heartburn on 2 separate days at level 4 on the 9 point Likert severity scale (point 3 on a 0-8 point scale) during the 7 day screening period prior to randomisation
  2. Completing < 90% (< 9 out of 10) of the time points with evaluable data on the e diary.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01493089

Locations
Poland
Department of Gastroenterology and Hepatology, Oncology Centre, Roentgena
Warsaw, Poland, 02-781
Sponsors and Collaborators
Norgine
Investigators
Principal Investigator: J Regula, MD Dept of Gastroenterology and Hepatology, Roentgena, Warsaw, Poland
  More Information

No publications provided

Responsible Party: Norgine
ClinicalTrials.gov Identifier: NCT01493089     History of Changes
Other Study ID Numbers: ZEG-01/2010 (GERD)
Study First Received: December 13, 2011
Results First Received: December 7, 2012
Last Updated: August 12, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Gastroesophageal Reflux
Heartburn
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Omeprazole
Omeprazole, sodium bicarbonate drug combination
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Proton Pump Inhibitors

ClinicalTrials.gov processed this record on July 20, 2014